New drug HS-20110 enters human testing for Hard-to-Treat cancers

NCT ID NCT06892379

Recruiting now Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20110
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if HS-20110 will effectively shrink tumors. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

BRCR Medical Center INC
RECRUITING

Tamarac, Florida, 33321, United States
Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
Fort Wayne Medical Oncology and Hematology
RECRUITING

Fort Wayne, Indiana, 46804, United States
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
SUN YAT-SEN University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.